[Use of antilymphocyte globulin in autoimmune nervous system diseases].
The pathogenetic bases for the indication of immunosuppression in multiple sclerosis are represented in a survey, rested upon experiences in the clinical compatability test of AHLG Dessau. The knowledge gained in animal experiments and epidemiology in recent years is considered and problems of membrane, slow-virus hypothesis, genetic problems and changes of immunoglobulins and lymphocytes are critically referred to.
D000914:Antibodies, Viral / Q000032:analysis; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000628:therapy*; D002462:Cell Membrane / Q000032:analysis; D002555:Cerebrospinal Fluid / Q000166:cytology; D003711:Demyelinating Diseases / Q000628:therapy; D004041:Dietary Fats; D005802:Genes, MHC Class II; D006801:Humans; D007165:Immunosuppression Therapy; D008214:Lymphocytes / Q000276:immunology; D009103:Multiple Sclerosis / Q000628:therapy*; D012897:Slow Virus Diseases / Q000628:therapy; D014777:Virus Diseases / Q000628:therapy
D000914:Antibodies, Viral; D000961:Antilymphocyte Serum; D004041:Dietary Fats
Anwendung von Antilymphozytenglobulin bei autoimmun bedingten Nervenerkrankungen.